Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04535531
Previous Study | Return to List | Next Study

A Phase 3 Molluscum Contagiosum Efficacy and Safety Study (B-SIMPLE4)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04535531
Recruitment Status : Completed
First Posted : September 2, 2020
Last Update Posted : August 13, 2021
Sponsor:
Collaborators:
Therapeutics, Inc.
Synteract, Inc.
Information provided by (Responsible Party):
Novan, Inc.

Brief Summary:
This is a phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 850 subjects 6 months of age and older with molluscum contagiosum (MC). Subjects or their caregivers will apply SB206 10.3% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study.

Condition or disease Intervention/treatment Phase
Molluscum Contagiosum Drug: SB206 10.3% berdazimer Drug: vehicle gel Phase 3

Detailed Description:

This is a phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 850 subjects 6 months of age and older with molluscum contagiosum (MC). After obtaining informed consent/assent, subjects who satisfy entry criteria will be randomized 1:1 (active:vehicle). Subjects receiving current treatment for MC at the time of the Screening Visit will enter a wash out period of up to 14 days prior to randomization.

Subjects or their caregivers will apply treatment once daily to all lesions identified at Baseline and new lesions that arise during treatment for a minimum of 4 weeks and up to 12 weeks. If the investigator determines all lesions are cleared at a visit, the treatment may stop. If treatment is stopped due to clearance, subjects will continue regularly scheduled visits through Week 24/ET2. Study drug will be dispensed through Week 12/ET1 in case of lesion recurrence between study visits. At each visit subsequent to stopping treatment due to clearance, the investigator will determine if new lesions have occurred since the last visit, and if so, the subject or caregiver will be instructed by the investigator to re-initiate treatment. If the subject or caregiver see new lesions or re-occurrence of lesions in between visits, they should treat these lesions until the next visit. No study drug will be provided after the Week 12 visit. The subject or caregiver will apply study drug to the individual lesions. Periocular lesions will be treated if the lesions are at least 2 cm from the edge of the eye. Subjects will visit the clinic in person at Screening/Baseline, Week 2, Week 4 (unless visit is performed remotely), Week 8, Week 12, and Week 24.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 891 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum
Actual Study Start Date : September 1, 2020
Actual Primary Completion Date : April 28, 2021
Actual Study Completion Date : July 28, 2021

Arm Intervention/treatment
Experimental: SB206 10.3% berdazimer
SB206 10.3% berdazimer topically once daily
Drug: SB206 10.3% berdazimer
Topically once daily
Other Name: SB206 12% berdazimer sodium

Placebo Comparator: vehicle gel
Vehicle gel topically once daily
Drug: vehicle gel
Topically once daily




Primary Outcome Measures :
  1. Complete clearance of all treatable MC at Week 12 [ Time Frame: 12 Weeks ]
    Proportion of subjects with complete clearance of all treatable MC at Week 12


Secondary Outcome Measures :
  1. A lesion count of 0 or 1 of all treatable MC at Week 12 [ Time Frame: 12 Weeks ]
    Proportion of subjects achieving a lesion count of 0 or 1 of all treatable MC at Week 12

  2. 90% reduction from Baseline in the number of all treatable MC at Week 12 [ Time Frame: 12 Weeks ]
    Proportion of subjects achieving at least a 90% reduction from Baseline in the number of all treatable MC at Week 12

  3. Complete clearance of all treatable MC at Week 8 [ Time Frame: 8 Weeks ]
    Proportion of subjects with complete clearance of all treatable MC at Week 8

  4. Change from Baseline in the number of all treatable MC at Week 4 [ Time Frame: 4 Weeks ]
    Percent change from Baseline in the number of all treatable MC at Week 4



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Be 6 months of age or older, and in good general health;
  2. Have a documented informed consent form signed by subject or a parent or legal guardian and an assent form as required;
  3. Have between 3 and 70 treatable MC lesions at Baseline;
  4. For women of childbearing potential (WOCBP): Must have a negative urine pregnancy test prior to randomization and must agree to use an effective method of birth control during the study; Note: WOCBP and effective methods of birth control are outlined in Section 9.4.
  5. Have a device (phone, tablet, personal computer, etc.) that will support remote visits, including a camera;
  6. Be willing and able to follow study instructions and likely to complete all study requirements, including remote study visits.

Exclusion Criteria:

  1. Have strongly suggested sexually transmitted MC and do not agree to refrain from sexual activities throughout the study period;
  2. Are immunosuppressed, have immunodeficiency disorder, or are on immunosuppressive treatment;
  3. Have significant injury on and/or surrounding MC that may impact ability to treat and count lesions;
  4. Have received treatment with topical calcineurin inhibitors or steroids on MC or within 2 cm of MC lesions within 14 days prior to Baseline;
  5. Have received treatment for MC during the 14 days prior to Baseline with podophyllotoxin, imiquimod, cantharidin, sinecatechins, topical retinoids, oral or topical zinc, or other homeopathic or over the counter (OTC) products including, but not limited to, ZymaDerm and tea tree oil, cimetidine and other histamine H2 receptor antagonists (including Zantac), or any agent that in the opinion of the investigator may be relevant - (e.g. wart therapies);
  6. Have received surgical procedures related to MC (e.g. cryotherapy, curettage) within 14 days prior to Baseline;
  7. Have MC only in periocular area;
  8. Female subjects who are pregnant, planning a pregnancy or breastfeeding;
  9. Have known hypersensitivity to any ingredients of SB206 or Vehicle Gel including excipients;
  10. Have participated in a previous study with a berdazimer containing product (i.e. SB204, SB206, SB208, SB414);
  11. Have more than one other family member participating in this study (NI-MC304);
  12. Have at least 1 family member currently participating in a study, other than this study, with a berdazimer containing product (i.e. SB204, SB206, SB208, SB414);
  13. Have participated in any other trial of an interventional investigational drug or device within 14 days or concurrent participation in another interventional research study;
  14. History or presence of clinically significant medical, psychiatric, or emotional condition that, in opinion of the investigator, would compromise the safety of the subject or the quality of the data.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04535531


Locations
Show Show 55 study locations
Sponsors and Collaborators
Novan, Inc.
Therapeutics, Inc.
Synteract, Inc.
Investigators
Layout table for investigator information
Study Director: Tomoko Maeda Chubachi, MD PhD Novan, Inc.
Layout table for additonal information
Responsible Party: Novan, Inc.
ClinicalTrials.gov Identifier: NCT04535531    
Other Study ID Numbers: NI-MC304
First Posted: September 2, 2020    Key Record Dates
Last Update Posted: August 13, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Molluscum Contagiosum
Poxviridae Infections
DNA Virus Infections
Virus Diseases
Infections
Skin Diseases, Viral
Skin Diseases, Infectious
Skin Diseases